Clinical

Dataset Information

0

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

ABSTRACT: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.

DISEASE(S): Angioimmunoblastic T-cell Lymphoma,Lymphoma,Cancer

PROVIDER: 2006457 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
| 2100536 | ecrin-mdr-crc
Clinical KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
| 2052967 | ecrin-mdr-crc
Clinical Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
| 2041970 | ecrin-mdr-crc
Clinical Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
| 2059705 | ecrin-mdr-crc
Clinical Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
| 2123001 | ecrin-mdr-crc
Clinical Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
| 2088557 | ecrin-mdr-crc
Clinical Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
| 2046609 | ecrin-mdr-crc
Clinical PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
| 2031022 | ecrin-mdr-crc
Clinical 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
| 2026481 | ecrin-mdr-crc
Clinical Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
| 2099626 | ecrin-mdr-crc